Welcome to LookChem.com Sign In|Join Free

CAS

  • or

193273-66-4

Post Buying Request

193273-66-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • Propanamide,2-amino-N-[(1R)-2-[(3aR)-2,3,3a,4,6,7-hexahydro-2-methyl-3-oxo-3a-(phenylmethyl)-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]-2-methyl- 193273-66-4

    Cas No: 193273-66-4

  • No Data

  • 1 Kilogram

  • 10000 Metric Ton/Month

  • Shanghai Upbio Tech Co.,Ltd
  • Contact Supplier
  • Propanamide,2-amino-N-[(1R)-2-[(3aR)-2,3,3a,4,6,7-hexahydro-2-methyl-3-oxo-3a-(phenylmethyl)-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]-2-methyl-

    Cas No: 193273-66-4

  • No Data

  • 1 Kilogram

  • 1 Metric Ton/Day

  • Shandong Hanjiang Chemical Co., Ltd.
  • Contact Supplier
  • Propanamide,2-amino-N-[(1R)-2-[(3aR)-2,3,3a,4,6,7-hexahydro-2-methyl-3-oxo-3a-(phenylmethyl)-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]-2-methyl-

    Cas No: 193273-66-4

  • No Data

  • No Data

  • 10000 Metric Ton/Month

  • Henan Wentao Chemical Product Co., Ltd.
  • Contact Supplier

193273-66-4 Usage

Uses

Treatment and prevention of frailty; treatment of congestive heart failure; treatment of catabolic illness (growth hormone secretagogue).

Check Digit Verification of cas no

The CAS Registry Mumber 193273-66-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,3,2,7 and 3 respectively; the second part has 2 digits, 6 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 193273-66:
(8*1)+(7*9)+(6*3)+(5*2)+(4*7)+(3*3)+(2*6)+(1*6)=154
154 % 10 = 4
So 193273-66-4 is a valid CAS Registry Number.
InChI:InChI=1/C28H35N5O4/c1-27(2,29)25(35)30-22(18-37-17-21-12-8-5-9-13-21)24(34)33-15-14-23-28(19-33,26(36)32(3)31-23)16-20-10-6-4-7-11-20/h4-13,22H,14-19,29H2,1-3H3,(H,30,35)/t22-,28-/m1/s1

193273-66-4Downstream Products

193273-66-4Relevant articles and documents

Practical synthesis of capromorelin, a growth hormone secretagogue, via a crystallization-induced dynamic resolution

Rose, Colin R.,Zawistoski, Michael P.,Lefker, Bruce A.,Mangano, F. Michael,Wright, Ann S.,Carpino, Philip A.

, p. 1000 - 1003 (2017)

A practical synthesis of capromorelin (1), a growth hormone secretagogue, is described that utilizes as a key step a crystallization-induced dynamic resolution (CIDR) of (±)-3a-benzyl-2-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3(3aH)-one [(±)-2] by L-tartaric acid salt formation, yielding (R)-2.L-tartaric acid in high chemical yield (>85%) and with diastereomeric excess (de) of ~98%. Treatment of (R)-2.L-tartaric acid with ammonium hydroxide provided (R)-2 without loss of chiral purity. In situ generated (R)-2 was coupled with (R)-3-(benzyloxy)-2-(2-(tert-butoxycarbonyl)-2-methylpropanamido)propanoic acid [(R)-3] to give predominantly a single diastereomer of N-Boc-protected capromorelin [(1R,3aR)-4]. This process was used to prepare bulk quantities of capromorelin from (±)-2 to support preclinical toxicology studies.

Treatment of insulin resistance with growth hormone secretagogues

-

, (2008/06/13)

This invention is directed to methods of treating insulin resistance in a mammal which comprise administering an effective amount of a compound of formula I, where the variables are defined in the specification, or the stereoisomeric mixtures, diastereomerically enriched, diastereomerically pure, enantiomerically enriched or enantiomerically pure isomers, or the pharmaceutically acceptable salts and prodrugs thereof to said mammal. The compounds of formula I are growth hormone secretagogues and as such are useful for increasing the level of endogenous growth hormone. In another aspect this invention provides certain intermediates which are useful in the synthesis of the foregoing compounds and certain processes useful for the synthesis of said intermediates and the compounds of formula I. This invention is further directed to methods comprising administering to a human or other animal a combination of a functional somatostatin antagonist such as an alpha-2 adrenergic agonist and a compound of formula I.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 193273-66-4